What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.
Overview
Robert I. Blum, president & CEO of Cytokinetics, Incorporated (NASDAQ:CYTK), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($82.02); post-transaction value based on July 13, 2026 market close ($82.24).
Details
Cytokinetics operates as a clinical-stage to commercial-stage biopharmaceutical enterprise with a market capitalization of roughly $10 billion, leveraging its proprietary muscle biology platform to develop targeted therapeutics for unmet medical needs in cardiac and skeletal muscle disorders. The company has achieved significant clinical validation with MYQORZO's market approval and maintains a robust pipeline of investigational compounds, positioning it as a specialized player in the rare disease and cardiology therapeutic space.
Source
Originally published at www.fool.com.